Skip to main content

Intellectual Property

Viewpoints

Filter by:

Patent Prosecution and Strategic Counseling Viewpoint Thumbnail

Overview of USPTO Webinar: Understanding Patenting in China

December 17, 2020 | Blog | By Christina Sperry, Paul Brockland

Patent protection in China has been a hot topic of discussion and strategy for U.S. companies. The U.S. Patent and Trademark Office (USPTO) China team within the USPTO's Office of Policy and International Affairs is a dedicated group of intellectual property (IP) attorneys and specialists with knowledge and experience on China manners from the U.S. law perspective as well as the Chinese law perspective.
Read more
Trademark Copyright Viewpoints Thumbnail

FDA Issues New Guidance on Drug Naming

December 17, 2020 | Blog | By Karen K. Won

Last week, the Food and Drug Administration (“FDA”) issued a pair of Guidance for Industry documents outlining best practices for developing proprietary names (i.e. brand names) for prescription and nonprescription human drug products. 
Read more
Patent Litigation Viewpoint Thumbnail

Is This Seat Taken? A Chinese IP Court Proclaims Its Authority to Declare Global FRAND Terms

December 7, 2020 | Blog | By Michael Renaud, James Wodarski, Matthew Galica

A Chinese Court recently decided that it has the willingness, and jurisdiction, to set a global licensing rate that is fair, reasonable, and non-discriminatory (“FRAND”) for standard essential patents (“SEP”). 
Read more
Patent Prosecution and Strategic Counseling Viewpoint Thumbnail

Rise of the Improper Markush Grouping Rejection and Biomolecules

November 18, 2020 | Blog | By Marc Morley, Jeff Giering

Read more
Patent Litigation Viewpoint Thumbnail
Recently in Nike, Inc. v. Skechers U.S.A., Inc., 2:17-cv-08509 (C.D. Cal.) (October 26, 2020), the U.S. District Court for the Central District of California granted-in-part and denied-in-part Defendant, Skechers U.S.A., Inc.’s (“Skechers”), motion to limit Plaintiff, Nike, Inc.’s (“Nike”), claim seeking attorney’s fees related to the infringement of its eight asserted design patents, resulting in the bifurcation of the willfulness issue from the trial on the merits.
Read more
Federal Circuit Appeals Viewpoint Thumbnail

In Hatch-Waxman litigation, Federal Circuit restricts venue under the TC Heartland to districts relating to ANDA filings

November 12, 2020 | Blog | By Adam Samansky, Peter Cuomo, Joe Rutkowski, Nana Liu

On November 5, 2020, the United States Court of Appeals for the Federal Circuit, in Valeant Pharmaceuticals N. Am. LLC v. Mylan Pharmaceuticals Inc., No. 19-2402, resolved a split among district courts over what constitutes “acts of infringement” sufficient to support venue in the context of a Hatch-Waxman litigation.  
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail
Building on Tip #4, one effective way to avoid institution and not address facts is to point out shortcomings in the petition’s application of KSR when asserting motivation to combine for an obviousness analysis. The Patent Trial and Appeal Board (“PTAB”) is an administrative tribunal that frequently encounters proposed grounds that challenged claims are obvious pursuant to 35 U.S.C. ¶103.
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail

Tip #4 for Avoiding IPR Institution: Don’t Argue Facts

November 9, 2020 | Blog | By Brad M Scheller, Serge Subach

We’ve previously written that the best defense to an IPR challenge is avoiding IPR institution altogether. In addition to the other tips discussed in this series of posts, another strategy for avoiding institution is focusing the Patent Owner’s Preliminary Response (“POPR”) on areas where the Petitioner failed to adequately support its argument.
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail

Tip #3 for Avoiding IPR Institution: Use Disclaimers Strategically

November 5, 2020 | Blog | By William Meunier, Peter Cuomo

Under U.S. patent law, “No inter partes review will be instituted based on disclaimed claims.”  37 C.F.R.  § 42.107(e).  And petitioners only need to demonstrate a reasonable likelihood of prevailing with respect to one challenged claim in order to secure a favorable institution from the PTAB. 35 U.S.C. § 314.  
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail
If you are a patent owner facing an inter partes review (“IPR”) or other post-grant review at the Patent Trial and Appeal Board (“PTAB”), your best chance of success is to convince the PTAB not to institute a trial.  But that does not mean that you should pack all of your substantive arguments about patentability into your preliminary response.
Read more
Trademark Copyright Viewpoints Thumbnail
As we reported in our July 7, 2020 blog post on the USPTO v. Booking.com B.V decision, the U.S. Supreme Court ruled that a proposed mark consisting of the combination of a generic term and a generic top-level domain, like “.com,” is not automatically generic and can be protected as a trademark under certain circumstances.
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail

Tip #1 for Avoiding IPR Institution: Litigation Venue Selection

October 29, 2020 | Blog | By Daniel Weinger, Michael Newman, Peter Cuomo

Venue selection is a critical component to any patent enforcement strategy, even before the inception of the PTAB as we know it today.  Venue now has even greater importance, as the speed of your patent case (i.e. time to trial) and stay statistics will have a direct impact on whether IPRs against your patents will institute in light of the Fintiv factors.
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail

Avoiding IPR Institution: Your Best Defense to an IPR Challenge

October 27, 2020 | Blog | By Peter Cuomo, William Meunier, Brad M Scheller

The United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) was once famously referred to by the former chief judge of the Federal Circuit, the honorable Randall Rader, as a patent death squad.
Read more
Patent Prosecution and Strategic Counseling Viewpoint Thumbnail

Procuring U.S. Patents without a Signed Assignment of Patent Rights

October 27, 2020 | Blog | By Christina Sperry, Mark Hammond

Increased employee mobility, health challenges, and the economic downturn due to the COVID-19 pandemic may result in more inventors than usual being unavailable to assign patent rights.  Fortunately, applicants may procure a U.S. patent even if an assignment document cannot be obtained for the application to be filed.  
Read more
Patent Litigation Viewpoint Thumbnail
The recent anti-suit injunction issued against InterDigital in its SEP litigation with Xiaomi is a somewhat predictable reaction to the recent UK Supreme Court decision against Huawei and ZTE.  One of the central arguments there was that the UK courts were trying to set themselves up as the international arbiter of FRAND disputes. 
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail

Fate of PTAB Judges and Decisions Now in Hands of Supreme Court

October 15, 2020 | Blog | By Michael Renaud, William Meunier, Monique Winters Macek

On October 13, 2020, the U.S. Supreme Court granted three petitions for writ of certiorari related to Arthrex v. Smith & Nephew addressing two issues that will determine the fate of PTAB judges and decisions.
Read more
Federal Circuit Appeals Viewpoint Thumbnail
In Network-1 Techs., Inc. v. Hewlett-Packard, No. 18-2338, the Federal Circuit reversed and vacated multiple aspects of the district court’s final judgment holding that Hewlett-Packard (HP) did not infringe U.S. Patent No. 6,218,930 (“the ’930 patent”) disclosing an apparatus and method for remotely powering Ethernet compatible equipment.
Read more
Viewpoint Thumbnail
In the latest decision addressing antitrust liability for FRAND commitments, Judge Barbara M. G. Lynn of the Northern District of Texas dismissed a complaint from Continental Automotive Systems, Inc. (“Continental”) alleging, inter alia, violations of §§ 1 and 2 of the Sherman Act, and declaratory judgment as to FRAND obligations against Avanci, LLC (“Avanci”) and various members of its patent pool (collectively, “Defendants”).
Read more
Trade Secrets Viewpoint Thumbnail

Fact-Specific Inquiry: Deciding Between Trade Secret and Patent Protection

September 15, 2020 | Blog | By Adam Samansky, Nicholas Armington

Innovations that are eligible for patent protection are often vital to a company’s revenue stream and profitability, but in some cases, opting for trade secret protection is a better strategic choice.
Read more

Explore Other Viewpoints: